Nevro, a startup waiting for approval of a device to treat back pain, raised $126 million in an IPO that priced higher than expected on Wednesday.
The Menlo Park company led by CEO Michael DeMane sold 7 million shares at $18, more than the 6.25 million shares it had projected and at a price that topped its announced range of between $15 and $17 a share.
The company was set to begin trading Thursday on the NYSE with the symbol of NVRO.
Help employers find you! Check out all the jobs and post your resume.
